pathological response

Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC

Vittorio Studiale, Medical Oncology Resident at University Hospital of Pisa, shared on X:

“Impressive pathological response rate (71%, pCR 35%) with neoadjuvant BOT/BAL in MSS colorectal cancer from the update of NEST-1 trial.”

Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC

Source: Vittorio Studiale/X

Agenus Balstilimab BOT/BAL BOT/BAL immunotherapy botensilimab cancer colorectal cancer ESMO ESMOGI24 European Society for Medical Oncology Garo Armen Jennifer Buell Mehraneh Jafari metastatic MSS colorectal cancer MSS CRC neoadjuvant BOT/BAL NEST-1 trial OncoDaily Oncology Pashtoon Kasi Steven O'Day Vittorio Studiale